In a groundbreaking development for the treatment of muscular dystrophies, IPS HEART received Orphan Drug Designation (ODD) from the U.S. FDA on January 13th, 2025, for its innovative stem cell therapy, GIVI-MPCs. GIVI-MPCs are mesenchymal progenitor cells derived from induced pluripotent stem cells (iPSCs) that have the potential to treat Becker Muscular Dystrophy (BMD). This milestone recognizes the therapy’s unprecedented ability to generate new skeletal muscle containing full-length dystrophin—a crucial protein missing or defective in individuals with BMD. [Read more…]
Dominance of Cellular Dynamics International (CDI) within iPSC Marketplace
Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.
In theory, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.
In this article:
- Life Science Business Unit
- iPSC Market Competitors
- Cellular Dynamics International, Owned by Fujifilm Holdings
- Cellular Dynamics and Shinya Yamanaka
- An Important Player in Stem Cell Research and Therapy
- Use of iPSCs in Drug Development and Discovery
- CDI’s Acquisition by FUJIFILM Holdings Corporation
- The Future of FUJIFILM CDI
Cellular Dynamics International and iPSC Therapy
Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.
iPSC Market Competitors
In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:
- Ocata Therapeutics
- RIKEN
- Kyoto University and CiRA
- Fate Therapeutics
- Megakaryon Corporation
- Cynata Therapeutics
There are also a number of companies specializing in iPSC product development, including:
- Allele Biotechnology
- ALSTEM Bio
- Applied Biological Materials (ABM)
- Applied StemCell
- Axol Bioscience
- BrainXell
- Cell Applications
- Cellular Dynamics International (a Fujifilm Company)
- EMD Millipore
- Minerva Biotechnologies
- Ncardia (formed through merger of Axiogenesis and Pluriomics)
- Neucyte
- Pluricell Biotech
- REPROCELL
- Sigma Aldrich (provides 350 iPSC lines through partnership with EBiSC)
- STEMCELL Technologies
- Stemgent (iPS Cell Business Unit owned by ReproCELL)
- Takara Bio
- Tempo Bioscience
- Thermo Fisher Scientific
- xCell Sciences
- And others
Fujifilm Cellular Dynamics Inc.
Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.
Could Cynata’s Cymerus™ Platform Be A Tool for Fighting the Pandemic?
What is the Cymerus™ technology and how could it potentially assist in the battle against Coronavirus cases on a global basis? Cymerus™ is a stem cell manufacturing platform being developed by Cynata Therapeutics Limited (ASX: CYP), an Australian regenerative medicine company.
The proprietary technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating mesenchymoangioblasts (MCAs). It then differentiates these cells into mesenchymal stem cells (MSCs). [Read more…]
Custom iPSC Engineering Services – 4 Reasons to Choose Applied StemCell
Applied StemCell Inc. (ASC) is a gene-editing company that offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications. Currently, the company is focused on the following areas:
- Cell line generation for bio-production and bioassays
- Patient-relevant cell models for personalized medicine
- Physiologically predictive animal and cellular models of human disease
Applied StemCell uses its TARGATT™ technology to specifically insert a gene-of-interest at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific knock-in technology was first established in mouse models, and ASC has successfully applied it to human cell lines.
ASC has leveraged this technology across various projects that combine the complementary CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression. [Read more…]
iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.
Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 20
- Next Page »